OncoHost Partners with Gustave Roussy Cancer Institute to Advance Predictive Markers for Immune-Related Adverse Events

Original Source here:

PREMIS study to further validate OncoHost's PROphetirAE™ predictor and improve patient safety in immunotherapy

BINYAMINA, Israel and CARY, N.C., Feb. 26, 2025 /PRNewswire/ -- OncoHost, a technology company transforming the approach to precision medicine for improved patient outcomes, today announced a collaboration with Gustave Roussy, the first European cancer center, to identify non-invasive biomarkers for immune-related adverse events (irAEs) in patients undergoing immunotherapy.

Immunotherapy, particularly immune checkpoint inhibitors targeting PD-1/PD-L1 and CTLA-4, has revolutionized cancer treatment by harnessing the immune system to fight tumors. However, these therapies can trigger severe and sometimes life-threatening autoimmune side effects, especially in combination regimens. Predicting which patients are at risk of developing these toxicities remains a significant challenge.

The PREMIS study, promoted by Gustave Roussy, is an interventional research aimed at identifying predictive biomarkers for irAEs in patients receiving immunotherapy. As part of this broader effort, OncoHost is partnering with Gustave Roussy to further validate its PROphetirAE™ test—an advanced tool that utilizes AI and biomarker analysis to assess patients' risk of developing irAEs. This collaboration supports the study's goal of enabling personalized treatment strategies that minimize toxicities and improve therapeutic outcomes.

The pioneering initiative designed specifically to identify biomarkers that can predict the onset of immune-related adverse events (irAEs), has enrolled 1,000 cancer patients receiving immunotherapy with monoclonal antibodies (anti-PD-1, anti-PD-L1, anti-CTLA4, and combinations). This unique study is built within a dedicated pharmacovigilance department, allowing for the systematic collection of key clinical data and comprehensive characterization of irAEs. "Identifying biomarkers allowing to predict irAE is now essential. It is a crucial step toward personalizing the management of patients receiving immunotherapy" said Dr. François-Xavier Danlos, a researcher coordinating this effort.

"This partnership represents a significant step forward in addressing one of the most pressing challenges in oncology today – predicting immune-related adverse events in immunotherapy patients," said Yehonatan Elon, PhD, CTO of OncoHost. "Understanding the mechanisms behind these toxicities is crucial to identifying at-risk individuals and managing toxicities effectively. This study is an important step toward achieving these goals, and we are honored to work with the Gustave Roussy team to improve patient safety and optimize the therapeutic journey."

Results from the translational analysis of the PREMIS study will not only authenticate OncoHost's PROphetirAE™ test, but also provide new insights into the biological mechanisms behind irAEs. The data will contribute to the development of prevention strategies and personalized approaches to managing immunotherapy-related toxicities, paving the way for safer and more effective treatments.

About OncoHost
OncoHost is a technology company headquartered in Binyamina, Israel, and Cary, North Carolina, transforming the approach to precision medicine for improved patient outcomes. OncoHost's proprietary platform, PROphet®, is a plasma-based, proteomic pattern analysis tool whose initial offering in non-small cell lung cancer (NSCLC) uses a single blood sample to guide first-line immunotherapy decision-making. The PROphetNSCLC™ test provides clear clinical utility by offering physicians crucial guidance on the optimal first-line immunotherapy treatment plan for each individual patient, with a significant effect on overall survival. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 40 sites and 1,700 patients recruited worldwide, OncoHost is well-positioned to lead precision diagnostics and biomarker development to the next stage.

For more information, visit www.oncohost.com, or follow OncoHost on LinkedIn, Twitter, Facebook and YouTube.

‍